U.S. markets closed

Avidity Biosciences, Inc. (RNA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
23.96+1.13 (+4.95%)
At close: 4:00PM EDT
Full screen
Loading interactive chart...
  • PR Newswire

    Avidity Biosciences to Participate in Upcoming Investor Conferences

    Avidity Biosciences, Inc. (NASDAQ: RNA) a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the Avidity management team will be participating at the following conferences:

  • PR Newswire

    Avidity Biosciences Announces Changes to its Board of Directors

    Avidity Biosciences, Inc. (Nasdaq: RNA) a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the appointment of experienced global commercial and operations executive, Eric Mosbrooker to its board of directors. Mr. Mosbrooker is an industry leader with expertise in building global commercial organizations, as well as marketing, market access, distribution, and compliance.

  • PR Newswire

    European Medicines Agency (EMA) Grants Orphan Designation for AOC 1001

    Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), announced that the European Commission (EC) has granted orphan designation for AOC 1001. The U.S. Food and Drug administration also granted orphan drug designation to AOC 1001 earlier this summer.